<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001062</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 278</org_study_id>
    <secondary_id>11254</secondary_id>
    <nct_id>NCT00001062</nct_id>
  </id_info>
  <brief_title>A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes</brief_title>
  <official_title>A Phase I Study of a Fixed-Schedule Regimen of Alternating Oral and Intravenous Ganciclovir for Treatment of Cytomegalovirus Retinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine whether alternating oral ganciclovir with intravenous ( IV ) ganciclovir can&#xD;
      prevent relapse of Cytomegalovirus ( CMV ) retinitis and improve quality of life in AIDS&#xD;
      patients.&#xD;
&#xD;
      A systemic treatment strategy for CMV retinitis is needed that will be effective yet&#xD;
      convenient to administer, without the need for a permanent indwelling IV catheter. Although&#xD;
      oral ganciclovir has been used as maintenance following induction with IV ganciclovir,&#xD;
      patients with reactivation of disease must be reinduced IV. A fixed-schedule regimen in which&#xD;
      oral and IV ganciclovir are alternated may prevent reactivation and progression of disease,&#xD;
      as opposed to the current therapeutic strategy in which changes in therapy are event-driven.&#xD;
      Also, the duration of intermittent IV therapy required to control disease may be short enough&#xD;
      to eliminate the need for an indwelling catheter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A systemic treatment strategy for CMV retinitis is needed that will be effective yet&#xD;
      convenient to administer, without the need for a permanent indwelling IV catheter. Although&#xD;
      oral ganciclovir has been used as maintenance following induction with IV ganciclovir,&#xD;
      patients with reactivation of disease must be reinduced IV. A fixed-schedule regimen in which&#xD;
      oral and IV ganciclovir are alternated may prevent reactivation and progression of disease,&#xD;
      as opposed to the current therapeutic strategy in which changes in therapy are event-driven.&#xD;
      Also, the duration of intermittent IV therapy required to control disease may be short enough&#xD;
      to eliminate the need for an indwelling catheter.&#xD;
&#xD;
      Patients receive IV induction with ganciclovir for 2 weeks followed by an alternating course&#xD;
      of 3 weeks of oral ganciclovir and 1 week of IV drug for four cycles (16 weeks). If CMV&#xD;
      retinitis fails to arrest after initial induction, IV ganciclovir is administered for an&#xD;
      additional 2 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">January 1998</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>25</enrollment>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Erythropoietin, G-CSF, or GM-CSF.&#xD;
&#xD;
          -  Antiretrovirals.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Evaluable CMV retinitis with photographable lesions.&#xD;
&#xD;
          -  Life expectancy of at least 6 months.&#xD;
&#xD;
          -  No active AIDS-defining opportunistic infections or malignancies that require&#xD;
             nephrotoxic or myelosuppressive therapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Evidence of retinal vascular or related infectious disease or other retinal lesions&#xD;
             that would interfere with the ability to detect responses to therapy or progression.&#xD;
&#xD;
          -  Corneal, lens, or vitreous opacification precluding funduscopic exam.&#xD;
&#xD;
          -  Clinically significant pulmonary or neurologic impairment other than seizure disorder&#xD;
             or CNS mass lesion.&#xD;
&#xD;
          -  Inability to obtain temporary IV access.&#xD;
&#xD;
          -  Requirement for permanent catheters for IV ganciclovir administration.&#xD;
&#xD;
          -  Uncontrolled diarrhea or nausea preventing ingestion of medicine.&#xD;
&#xD;
          -  Known hypersensitivity to IV or oral ganciclovir.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Biologic response modifiers.&#xD;
&#xD;
          -  Interferon.&#xD;
&#xD;
          -  Related investigational agents.&#xD;
&#xD;
          -  CMV prophylaxis.&#xD;
&#xD;
          -  Systemic acyclovir.&#xD;
&#xD;
          -  Any nephrotoxic agent.&#xD;
&#xD;
          -  Any concomitant therapy that would prohibit use of ganciclovir.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior treatment for CMV retinitis.&#xD;
&#xD;
          -  More than 4 months of prior ganciclovir or foscarnet, or within 4 weeks prior to study&#xD;
             entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holland GN</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Hardy WD</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University A2201</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Danner SA, Matheron S. Cytomegalovirus retinitis in AIDS patients: a comparative study of intravenous and oral ganciclovir as maintenance therapy. AIDS. 1996 Dec;10 Suppl 4:S7-11.</citation>
    <PMID>9110064</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infusions, Intravenous</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Cytomegalovirus Retinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
    <mesh_term>Retinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

